News

Amarantus BioScience Holdings (AMBS), a company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, recently announced that it has completed research in which mesencephalic-astrocyte-derived neurotrophic factor (MANF) was administered to the substantial nigra and the putamen of pigs by convection-enhanced…

According to a recent survey, there is a need for a Parkinson’s disease organization that is committed to and focused on a grassroots voice and the consolidation of resources. In response to this, “Parkinson’s People for Awareness & Unity,” an Indiegogo campaign, was recently created to raise money…

Italian pharmaceutical company Zambon S.p.A. and Newron Pharmaceuticals S.p.A. have announced plans to launch Xadago, a drug therapy for mid- to late-stage Parkinson’s disease, in Germany. The release of the treatment is the result of a partnership between the two companies, and Germany will become the first country to commercialize the drug. “The launch of…

Amarantus BioScience Holdings, a biotechnology company developing diagnostic and therapeutic products to address neurological disorders and orphan conditions, recently announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a United States Patent Application entitled, “Pharmacological Treatment of Parkinson’s Disease.” The patent will address intellectual property protection for eltoprazine, Amarantus’s lead…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Bachmann-Strauss Dystonia and Parkinson Foundation (BSDPF) have celebrated a new collaborative alliance at an event in which the MJFF awarded the inaugural Bachmann-Strauss Prize for Excellence in Dystonia Research. The prize was awarded for distinguished groundbreaking advancements and discoveries in the field…

The 27th annual Supercomputing Conference (SC15), formally known as The International Conference for High Performance Computing, Networking, Storage and Analysis, will be held in the Austin Convention Center at Austin, Texas from November 15-20 2015, with an attendant exhibition to be open from November 16-19. The conference, sponsored by…

It was recently announced that The Michael J. Fox Foundation (MJFF) for Parkinson’s Research acquired from Imago Pharmaceuticals several research tools based on the parkin protein in order to advance the biological study of the disease and the development of therapeutic drugs. Parkinson’s disease is a progressive neurodegenerative…

A recent study published in the journal ACS Nano revealed a new approach based on nanoparticles and the neurotransmitter dopamine that can successfully reverse Parkinson’s-like symptoms in rodent models of the disease. The study is entitled “Trans-Blood Brain Barrier Delivery of Dopamine-Loaded Nanoparticles Reverses…

Researchers from the University of North Carolina at Chapel Hill utilized exosomes, minuscule bubbles of fat and protein that cells produce naturally, in order to bypass the body’s defenses and deliver strong antioxidants directly into the brain to offer treatment for Parkinson’s disease. The study was published in the Journal of Controlled…

The Michael J. Fox Foundation for Parkinson’s Research and Prothena Corporation announced a collaboration to find new biomarkers for Parkinson’s disease (PD) progression. They will focus on molecules related to alpha-synuclein, a protein found in the brain of people with PD that may contribute to the cause of the disease. A biomarker…